Log in or register to see all Alerts
New HTA Decisions in Scotland
March 2021
Drug name
ALUNBRIG® (brigatinib)
Company
Takeda UK Ltd
Decision date
04/12/2020
Therapeutic area
Cancer
Therapeutic sub area
Lung cancer
Decision
Recommended
Indication
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
Decision Detail
Following an abbreviated submission, brigatinib (ALUNBRIG®) is accepted for use within NHS Scotland. This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Summary
Medicines within this therapeutic class have been accepted via the orphan process for this indication. Brigatinib (ALUNBRIG®) offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors for this indication.